Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study

Pommier Rodney F.; Fisher George A.; Wolin Edward M.; Liyanage Nilani; Lowenthal Susan Pitman; Mirakhur Beloo; Shaheen Montaser; Vinik Aaron I.

首页> 外文期刊>Pancreas >Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study

【24h】

Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study

机译：甘油酯仓库/自凝胶症状综合征症状综合征（CS）患者，患者以前对octreotide响应的神经内分泌肿瘤（网）：患者报告的患者报告的患者的患者患者3阶段选择

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pancreas》 |2018年第3期|共1页
作者
Pommier Rodney F.; Fisher George A.; Wolin Edward M.; Liyanage Nilani; Lowenthal Susan Pitman; Mirakhur Beloo; Shaheen Montaser; Vinik Aaron I.;
展开▼
作者单位

Oregon Hlth &

Sci Univ Portland OR 97201 USA;

Stanford Univ Sch Med Stanford CA 94305 USA;

Montefiore Einstein Ctr Canc Care New York NY USA;

Ipsen Paris France;

Ipsen Biopharmaceut Basking Ridge NJ USA;

Ipsen Biopharmaceut Basking Ridge NJ USA;

Univ Arizona Ctr Canc Tucson AZ USA;

Eastern Virginia Med Sch Norfolk VA 23501 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study [J] . Pommier Rodney F., Fisher George A., Wolin Edward M., Pancreas . 2018,第3期

机译：甘油酯仓库/自凝胶症状综合征症状综合征（CS）患者，患者以前对octreotide响应的神经内分泌肿瘤（网）：患者报告的患者报告的患者的患者患者3阶段选择
2. Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Double-blind and Open-label Phases [J] . Fisher George A. Jr., Wolin Edward M., Kunz Pamela L., Pancreas . 2017,第3期

机译：甘油酯仓库/自凝胶对症状综合征（CS）对症控制的疗效疗效肿瘤患者：选举前瞻性，随机，双盲和开放标签阶段的随访分析
3. Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study [J] . Fisher George A. Jr., Wolin Edward M., Kunz Pamela L., The American Journal of Gastroenterology . 2016,第Suppla1期

机译：从ELECT开放标签研究中，兰瑞肽Autogel / Depot（LAN）对神经内分泌肿瘤（NET）患者类癌综合征（CS）进行对症治疗的长期疗效
4. Patient‐Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized Placebo‐Controlled Double‐Blind and 32‐Week Open‐Label Study [O] . George A. Fisher Jr., *, Edward M. Wolin, 2018

机译：兰瑞肽贮库/自动凝胶治疗的神经内分泌肿瘤患者的腹泻和潮红症状报告患者控制：来自一项随机安慰剂对照双盲和32周开放标签研究的结果
5. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. [O] . Ruszniewski P1, Valle JW2, Lombard-Bohas C3, Cuthbertson DJ4, Perros P5, Holubec L6, Delle Fave G7, Smith D8, Niccoli P9, Maisonobe P10, Atlan P10, Caplin ME11, SYMNET study group 2016

机译：兰瑞肽Autogel / Depot对类癌综合征的患者报告结局：一项国际观察性研究。

Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study

著录项

相似文献

相关主题

期刊订阅